2018: Briefing note on NIH proposed license to Gilead for CD-30 CAR T technology

Contact: Kim Treanor 202-332-2670; kim.treanor@keionline.org January 5, 2018 The National Institutes of Health (NIH) has proposed an exclusive license with Gilead for certain patent applications for inventions that target CD-30 proteins and CAR T technologies. The proposed license is to… Continue Reading

General Statement of Knowledge Ecology International – Sixty-First Series of Meetings of the Assemblies of the Member States of WIPO (WIPO Assemblies)

General Statement of Knowledge Ecology International – Sixty-First Series of Meetings of the Assemblies of the Member States of WIPO (WIPO Assemblies) Agenda item 5 – General Statements 21 September 2020 In relation to the COVID-19 response, Knowledge Ecology International… Continue Reading

WIPO Side event: Appraising Progress of WHO’s COVID-19 Technology Access Pool (C-TAP)

DATE: Tuesday, 22 September 2020 TIME: 18:00 CEST to 19:00 CEST CONVENER: Knowledge Ecology International (KEI) REGISTRATION: Please contact thiru [at] keionline.org On occasion of the 61st Series of Meetings of the WIPO General Assembly, Knowledge Ecology International (KEI) is… Continue Reading

Joint letter to WHO formally requesting the R&D Observatory to play a more relevant role in the COVID-19 response

On Friday, 28 August 2020, six groups including Corporación Innovarte, Health Action International, Knowledge Ecology International, Medicines Law & Policy, Pharmaceutical Accountability Foundation, and Wemos wrote a joint letter to the World Health Organization’s (WHO) Chief Scientist, Dr. Soumya Swaminathan,… Continue Reading

KEI and UACT Comments to NIH on Proposed Exclusive License to Connectyx

On Friday September 11, 2020, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Anti-CD56 as an Antibody-Drug Conjugate… Continue Reading

BARDA is investigating Moderna’s failures to disclose BARDA funding in patent applications

(More on Moderna here: https://www.keionline.org/moderna) KEI received a letter Dr. Gary Disbrow, the Acting Director of BARDA, just before noon today. BARDA2KEI.Moderna.Patent.Disclosures.20200903 The BARDA investigation follows the announcement on Saturday that DARPA was also investigating DARPA’s failures to disclose DARPA… Continue Reading

KEI request to BARDA concerning Moderna obligations to disclose federal funding in patent applications

On September 2, 2020, Knowledge Ecology International (KEI) sent a letter to the Biomedical Advanced Research and Development Authority (BARDA) regarding a potential failure by Moderna, Inc. to disclose federal funding in patents supported by BARDA. KEI requested information concerning… Continue Reading

KEI and UACT Comments Regarding NIH Exclusive License to ONK Therapeutics

(Update: The NIH has provided a response to our comments on August 31, 2020) On August 28, 2020, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) submitted comments to the National Institutes of Health (NIH) “Prospective… Continue Reading

Moderna

KEI Reports and Posts 2020. September 4. BARDA is investigating Moderna’s failures to disclose BARDA funding in patent applications. https://www.keionline.org/33907 2020. September 2. KEI request to BARDA concerning Moderna obligations to disclose federal funding in patent applications. https://www.keionline.org/33892 2020. August… Continue Reading

KEI Comments Regarding NIH Exclusive License to PreciThera

(Update: The NIH provided a response to our comments on August 24, 2020) On August 20, 2020, Knowledge Ecology International (KEI) submitted comments regarding the prospective grant of an exclusive license by the National Institutes of Health (NIH) to PreciThera,… Continue Reading